Iolyx Therapeutics Announces Promising Phase II Results for ILYX-002 in Autoimmune Dry Eye Disease
ILYX-002 shows 3x greater corneal healing effect compared to current therapies on the market. Iolyx Therapeutics (California, United States), a…
Nicox’s NCX 470 Shows Dual IOP-Lowering Promise in Whistler Phase IIIb Trial
New data sheds light on how Nicox’s eye drop may improve outflow and reduce pressure—twice over. Nicox (Sophia Antipolis, France)…
popular posts
latest posts
